Key terms

About APLS

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest APLS news

May 15 5:23am ET 3 Best Stocks to Buy Now, 5/15/2024, According to Top Analysts by TipRanks May 14 9:08pm ET Apellis Pharmaceuticals: A Strong Buy on Syfovre’s Performance and Market Potential by TipRanks May 14 8:19am ET Apellis refinances existing debt with up to $475M credit facility by TipRanks May 13 7:00pm ET Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX) by TipRanks May 10 2:03am ET Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS) by TipRanks May 10 1:34am ET Strong Performance and Growth Potential Affirm Buy Rating for Apellis Pharmaceuticals by TipRanks May 07 4:15pm ET Buy Rating Reaffirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Robust Financial Outlook by TipRanks May 03 11:21am ET Biotech Alert: Searches spiking for these stocks today by TipRanks May 02 11:10am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Apr 30 2:38pm ET Jefferies view on safety of Apellis’ Syfovre remains unchanged by TipRanks Apr 29 6:50am ET Apellis price target lowered to $52 from $60 at Mizuho by TipRanks Apr 26 11:45am ET Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential by TipRanks Apr 26 7:17am ET Apellis announces pegcetacoplan MAA review has been reset to Day 180 by TipRanks Apr 26 3:08am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG) by TipRanks Apr 26 2:24am ET Impact of Izervay’s Growth on Apellis Pharmaceuticals: Maintaining a Hold Rating Amidst Rising Competition by TipRanks Apr 25 10:15am ET Maintaining Market Dominance: Strong Buy Rating on Apellis Pharmaceuticals with a Target Price of $85 by TipRanks Apr 18 6:45am ET Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS) by TipRanks Apr 18 1:10am ET Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS) by TipRanks Apr 15 6:20am ET Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS) by TipRanks Apr 09 6:40am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD) by TipRanks Mar 29 4:30am ET Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Apellis Pharmaceuticals (APLS) by TipRanks Mar 29 4:20am ET Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE) by TipRanks Mar 19 7:10am ET Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE) by TipRanks Mar 11 7:09am ET Apellis appoints Philip Ferrone as chief medical retina advisor by TipRanks Mar 07 12:00am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Laboratory (LH), Apellis Pharmaceuticals (APLS) and Iovance Biotherapeutics (IOVA) by TipRanks Mar 04 7:10am ET EyePoint appoints Ribeiro as Chief Medical Officer by TipRanks Mar 04 6:27am ET Apellis price target raised to $89 from $87 at UBS by TipRanks Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 28 11:59am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 28 8:44am ET Apellis price target raised to $67 from $60 at Wedbush by TipRanks Feb 28 7:40am ET Apellis price target raised to $84 from $77 at BofA by TipRanks

No recent press releases are available for APLS

APLS Financials

1-year income & revenue

Key terms

APLS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

APLS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Dave Calhoun, chief executive officer of Boeing Co., center right, on Capitol Hill in Washington, DC, US, on Wednesday, Jan. 24, 2024. The company is working to assure airline customers and the Federal Aviation Administration that its jets are safe after a January 5 accident, which involved a faulty door panel on a 737 Max 9 aircraft operated by Alaska Airlines.
Samuel Corum/Bloomberg/Getty Images
Boeing shareholders vote to approve $33 million CEO pay package
ZHANGYE, CHINA - APRIL 16, 2024 - Workers check photovoltaic panels before packing at the New Material 800MW high-efficiency photovoltaic module production line in Zhangye city, Gansu province, China, April 16, 2024.
CFOTO/Future Publishing/Getty Images
Biden’s tariffs on Chinese imports are boosting these beaten-down stocks
Traders work on the floor of the New York Stock Exchange on May 16, 2024. Wall Street is buoyed by hopes the Federal Reserve will pull back on its restrictive monetary policy after data showed inflation is beginning to ease.
Spencer Platt/Getty Images
Dow briefly tops 40,000 for first time but ends the day lower
Shoppers at a Walmart store in Secaucus, New Jersey, US, on Tuesday, March 5, 2024. Walmart is revamping more than 800 store locations and adding high-end products.
Gabby Jones/Bloomberg/Getty Images
Walmart’s business surges as shoppers hunt for low prices